An NF‐κB activation inhibitor, PDTC, was used at 20 μM in bladder tumour cell lines, and the blockade of NF‐κB activation significantly decreased CPS1 expression (Figure 2D). This evidence concerns the gene CPS1 and urinary bladder neoplasm.